Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Jashodeep Datta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5052-7586; OpenAlex author ID A5110169364. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers · 2025: 4 papers

Papers 8

  1. Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.70130↗
  2. Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic c… Last author DOI 10.1007/s00262-025-04096-y↗
  3. CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Alcoholic Pancreatitis. Co-author DOI 10.1016/j.jcmgh.2025.101606↗
  4. Targeting CREB remodels the immune microenvironment to enhance immunotherapy responses in pancreatic cancer Co-author DOI 10.64898/2025.12.04.691935↗
  5. Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi-institutional ana… Last author DOI 10.1002/jso.27798↗
  6. Improving patient stratification and selection for curative-intent treatment in localized pancreatic cancer. Last author DOI 10.21037/hbsn-23-668↗
  7. Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0083↗
  8. Investigational biomarkers for pancreatic adenocarcinoma: where do we stand? Co-author DOI 10.1097/smj.0000000000000088↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nipun B. Merchant · 7 shared papers, 2021–2025 · strength 1.32
  2. Haleh Amirian · 5 shared papers, 2024–2025 · strength 0.99
  3. Siddharth Mehra · 4 shared papers, 2021–2025 · strength 0.72
  4. Nagaraj S. Nagathihalli · 4 shared papers, 2021–2025 · strength 0.72
  5. Erin M. Dickey · 3 shared papers, 2024–2025 · strength 0.60
  6. Caitlin A. Hester · 3 shared papers, 2024–2025 · strength 0.60
  7. Mary P Martos · 3 shared papers, 2024–2025 · strength 0.60
  8. Iago De Castro Silva · 3 shared papers, 2021–2025 · strength 0.53
  9. Austin R. Dosch · 3 shared papers, 2021–2025 · strength 0.50
  10. Supriya Srinivasan · 3 shared papers, 2021–2025 · strength 0.50
  11. Peter J. Hosein · 2 shared papers, 2024–2025 · strength 0.44
  12. Ifeanyichukwu Chinedu Ogobuiro · 2 shared papers, 2024–2025 · strength 0.38
  13. David A. Kooby · 2 shared papers, 2024–2025 · strength 0.37
  14. Alexander A. Parikh · 2 shared papers, 2024–2025 · strength 0.37
  15. Daniel Erik Abbott · 2 shared papers, 2024–2025 · strength 0.37
  16. Syed Nabeel Zafar · 2 shared papers, 2024–2025 · strength 0.37
  17. Shishir Kumar Maithel · 2 shared papers, 2024–2025 · strength 0.37
  18. Samara P. Singh · 2 shared papers, 2021–2025 · strength 0.31
  19. Christine Isabelle Rafie · 1 shared paper, 2025 · strength 0.22
  20. Nilesh Deshpande · 1 shared paper, 2025 · strength 0.22
  21. Syed Ameen Ahmad · 1 shared paper, 2025 · strength 0.21
  22. Kawther Abdilleh · 1 shared paper, 2025 · strength 0.21
  23. Anna Bianchi · 1 shared paper, 2025 · strength 0.20
  24. Tulasigeri M. Totiger · 1 shared paper, 2025 · strength 0.20
  25. Michael Nathan VanSaun · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.